Russel Vought to Get NIH Grant Veto Power
▼ Summary
– A recent White House meeting revealed a conflict between NIH Director Jay Bhattacharya and OMB Head Russell Vought regarding political control over research funding.
– Reports indicate the administration is drafting an executive order to grant Vought veto power over every individual grant awarded by the NIH.
– This move follows previous attempts by Vought to terminate grants on pandemic preparedness and health disparities, which were rejected by Congress and voided by courts.
– The NIH manages a $47 billion budget that supports critical biomedical research and the biotechnology industry through grants to academic institutions.
– Vought’s proposed rules aimed to make political considerations key determinants in funding decisions, but these have been put on hold by Congress.
Russell Vought is poised to gain significant control over biomedical research funding, with reports indicating that the White House is drafting an executive order to grant the Office of Management and Budget (OMB) director veto power over individual National Institutes of Health (NIH) grants. This development follows a contentious internal struggle within the administration, where NIH Director Jay Bhattacharya reportedly lost a battle against efforts to politicize scientific funding decisions.
According to initial reports from The Washington Post, which have since been corroborated by The New York Times and Politico, the proposed directive would allow Vought to block specific grants at his discretion. This move represents a major escalation in the ongoing tension between political appointees and scientific leadership, shifting the balance of power away from peer-reviewed merit and toward administrative oversight.
A History of Friction
The NIH remains the world’s largest funder of biomedical research, operating on a budget of approximately $47 billion,a sum that exceeds the combined resources of the next ten largest research funders. This financial engine supports everything from fundamental biological studies to clinical trials, playing a critical role in sustaining the biotechnology sector and advancing academic research across universities. Despite its massive scale and impact, the agency has become a focal point for ideological conflicts within the current administration.
Immediately after President Trump returned to office, the administration moved to terminate numerous grants focused on pandemic preparedness and health disparities. Officials also proposed slashing the NIH budget by nearly 50%, a drastic reduction that was ultimately blocked by Congress. Furthermore, a court voided the policy underlying the grant terminations, citing legal irregularities. These defeats did not deter OMB officials; instead, they prompted Russell Vought to devise alternative mechanisms to exert influence over the agency’s spending priorities.
Political Criteria Replace Scientific Merit
In response to these setbacks, Vought proposed new regulations that would embed political considerations as primary factors in grant approval processes. Such rules would effectively allow ideological alignment to override traditional scientific evaluation metrics. However, Congress intervened again, placing these proposed rules on hold. Now, rather than relying on legislative changes or regulatory revisions, the administration appears to be pursuing an executive order to bypass congressional checks entirely.
This strategy aims to consolidate authority over research funding in the hands of the OMB, ensuring that political objectives drive allocation decisions. If enacted, the executive order would mark a significant departure from the historical norm of relative independence for the NIH, potentially reshaping the landscape of American biomedical research by subjecting every grant award to political scrutiny.
(Source: Ars Technica)
